FDA 483 OBSERVATION · #43 OF 1,923 MOST-CITED
Monitoring - adequacy
FDA cited this observation 536 times across 478 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Monitoring of the critical control points was inadequate — not performed at the required frequency, not properly recorded, or not designed to actually detect loss of control at the CCP.
Why FDA writes it — Monitoring is how you know a critical control point is staying within its critical limit. Inadequate monitoring means a deviation can occur undetected, defeating the entire purpose of the CCP — so FDA cites monitoring gaps as a direct control failure.
- Monitor each critical control point at a frequency sufficient to ensure the critical limit is consistently met.
- Use monitoring methods and instruments appropriate to the parameter, and keep them calibrated.
- Record monitoring results as they are taken (contemporaneously), with enough detail to show control.
- Ensure the person monitoring understands what an out-of-limit result requires.
- Monitoring frequency too low to catch a deviation before affected product moves on.
- Records completed after the fact rather than at the time of monitoring, so lapses are not caught in time.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.3× the rate of the average FDA-cited firm (10.3% vs 7.8%), across 478 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Your HACCP plan lists monitoring procedures and frequencies that do not ensure compliance with the critical limit.
Your HACCP plan lists monitoring frequencies that do not ensure compliance with the critical limit.
Your HACCP plan lists monitoring procedures and frequencies that do not ensure compliance with the critical limit.
Your HACCP plan lists monitoring procedures and frequencies that do not ensure compliance with the critical limit.
Your HACCP plan lists monitoring frequencies that do not ensure compliance with the critical limit.
Your HACCP plan lists monitoring procedures and frequencies that do not ensure compliance with the critical limit.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →